Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial

Table 1

Characteristics of subjects by mifepristone treatment groups (Values are presented as average ± SD⁺ or 𝑛 (%)).

Characteristics	2.5 mg	5 mg
	(𝑛=110)	(𝑛=110)
Age (years)	39.6±6.0	39.0±5.9
Body mass index (kg/m^2)	24.9±3.7	25.2±4.0
Gravidity	2.7±2.2	2.6±2.2
Parity	0.6±0.8	0.6±0.7
Abortion	1.6±1.9	1.4±1.7
Fibroids volume (cc)	136±129	112±118
Uterine volume (cc)	455±314	426±305
Endometrial thickness (mm)	6.8±1.9	6.8±2.5
Hemoglobin (g/dL)	10.4±1.7	10.5±1.7
Aspartate aminotransferase (IU)	23.5±9.0	22.9±9.5
Alanine aminotransferase (IU)	20.7±8.7	19.8±9.2
Race
White	32 (29.1)	27 (24.5)
Black	36 (32.7)	49 (44.5)
Afro-Cuban	42 (38.2)	34 (31.0)

+SD: Standard deviation.